Guo Liping, Niu Huaiming, Li Jun, Shao Xin, Li Na, Sun Yuehui, Ma Yan, Wang Haixiong
Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, 030000, China.
Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, 030000, China; General practice, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, 030000, China.
Biochem Biophys Res Commun. 2025 Sep 1;777:152168. doi: 10.1016/j.bbrc.2025.152168. Epub 2025 Jun 6.
Heart failure (HF) is characterized by pathological cardiac remodeling, leading to myocardial apoptosis, hypertrophy, and fibrosis. However, prognosis remains poor despite strides made in treatment regimens. Traditional Chinese Medicine (TCM) has been used to treat cardiovascular disorders, with evodiamine, an alkaloid derived from Tetradium ruticarpum, being identified for its cardioprotective effects. Although its potential to inhibit fibrosis and hypertrophy has been recognized, the underlying molecular mechanisms remain insufficiently understood. In this study, the cardioprotective effects of evodiamine were first evaluated in a transverse aortic constriction (TAC)-induced HF rat model and isoproterenol (ISO)-treated cardiomyocytes. Significant improvements in cardiac function and quantified reductions in apoptosis, hypertrophy, and fibrosis were observed following evodiamine treatment. Network pharmacology was subsequently applied to predict the molecular targets of evodiamine in HF, using data from the TCMSP and BATMAN-TCM databases and integrating differential gene expression analysis from an ISO-induced HF model (GSE225149). Gene enrichment and protein-protein interaction (PPI) network analyses highlighted key signaling pathways, including calcium signaling, and identified potential targets such as CD47. Experimental validation in both models confirmed that evodiamine modulated calcium signaling, specifically inhibiting CaMKII and RYR2 phosphorylation, and downregulated CD47 expression. Furthermore, CD47 overexpression attenuated evodiamine's protective effects and activated CaMKII, demonstrating a critical role for CD47, potentially through the CaMKII pathway, in mediating evodiamine's actions. These findings provide new insights into the cardioprotective mechanisms of evodiamine, highlighting its potential as a therapeutic agent for heart failure. Further molecular studies are recommended to fully identify its therapeutic benefits.
心力衰竭(HF)的特征是病理性心脏重塑,导致心肌细胞凋亡、肥大和纤维化。然而,尽管治疗方案取得了进展,但其预后仍然很差。中医(TCM)已被用于治疗心血管疾病,吴茱萸碱是一种从吴茱萸中提取的生物碱,已被证实具有心脏保护作用。尽管其抑制纤维化和肥大的潜力已得到认可,但其潜在的分子机制仍未得到充分了解。在本研究中,首先在横断主动脉缩窄(TAC)诱导的HF大鼠模型和异丙肾上腺素(ISO)处理的心肌细胞中评估了吴茱萸碱的心脏保护作用。吴茱萸碱治疗后,观察到心脏功能显著改善,细胞凋亡、肥大和纤维化定量减少。随后应用网络药理学预测吴茱萸碱在HF中的分子靶点,使用来自TCMSP和BATMAN-TCM数据库的数据,并整合来自ISO诱导的HF模型(GSE225149)的差异基因表达分析。基因富集和蛋白质-蛋白质相互作用(PPI)网络分析突出了关键信号通路,包括钙信号通路,并确定了潜在靶点,如CD47。在两个模型中的实验验证证实,吴茱萸碱调节钙信号通路,特别是抑制CaMKII和RYR2磷酸化,并下调CD47表达。此外,CD47过表达减弱了吴茱萸碱的保护作用并激活了CaMKII,表明CD47可能通过CaMKII途径在介导吴茱萸碱的作用中起关键作用。这些发现为吴茱萸碱的心脏保护机制提供了新的见解,突出了其作为心力衰竭治疗药物的潜力。建议进一步进行分子研究以充分确定其治疗益处。